Ameliorative Processes of Beta-Carotene in Streptozotocin-Induced Diabetic Vascular Dementia in Rats

Beta-carotene (BC) is a precursor of vitamin A and an excellent antioxidant. It protects the vascular system. Vascular dementia (VaD) is one of the aging disorders causing memory dysfunction. The available medicines for the management of VaD are limited. The present study aimed to evaluate the ameliorative effect of BC in streptozotocin (STZ)-induced diabetic VaD in rats. Diabetic VaD was induced through the administration of nicotinamide (NA, 50 mg/kg; i.p.) and STZ (50 mg/kg; i.p.). The test compound BC (50 and 100 mg/kg; p.o.) and reference compound donepezil (1 mg/kg; p.o.) were administered for 15 consecutive days. Cognitive changes were assessed by transfer latency (TL) using the elevated plus maze (EPM) test. The changes in acetylcholinesterase (AChE) activity were estimated in the septohippocampal system of rat brains. The administration of STZ caused significant changes in cognitive functions (increased TL) as compared to the normal group. BC ameliorated the anxiety-related cognitive behavior and neurotransmitter (elevated AChE) changes provoked by diabetic VaD. Therefore, BC could be a potential therapeutic candidate in the management of VaD.

Automated summary

This study evaluated the ameliorative effect of beta-carotene in a rat model of diabetic vascular dementia. The results showed that beta-carotene improved cognitive function and normalized neurotransmitter changes, suggesting its potential as a therapeutic agent for the management of vascular dementia.